Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Craniocervical decompression in patients with mucopolysaccharidosis VI: development of a scoring system to determine indication and outcome of surgery.

  • Read more about Craniocervical decompression in patients with mucopolysaccharidosis VI: development of a scoring system to determine indication and outcome of surgery.

Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management.

  • Read more about Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management.

Diagnosing mucopolysaccharidosis IVA.

  • Read more about Diagnosing mucopolysaccharidosis IVA.

Anaesthesia and airway management in mucopolysaccharidosis.

  • Read more about Anaesthesia and airway management in mucopolysaccharidosis.

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy.

  • Read more about Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy.

Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).

  • Read more about Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.

  • Read more about Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.

Functional characterization of the novel intronic nucleotide change c.288+9C>T within the BCKDHA gene: understanding a variant presentation of maple syrup urine disease.

  • Read more about Functional characterization of the novel intronic nucleotide change c.288+9C>T within the BCKDHA gene: understanding a variant presentation of maple syrup urine disease.

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.

  • Read more about Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.

Pagination

  • Previous page ‹‹
  • Page 2
Subscribe to Journal of inherited metabolic disease

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List